- IXICO, the brain health company, reports an operating loss of £2.9 million for the year to the end of September - up from £1.4m last time.

Revenues were flat at £3.1 million and the group had other income of £0.8 million (2015: £1.1 million).

Commercial highlights:

Highlights Commercial

- Continued expansion of the customer base and launch of Assessa PML platform

- Assessa PML partnership with Biogen to improve the risk profile of a multiple sclerosis drug

- New sales wins of £4.7 million

* 4 new contracts in Alzheimer's disease at combined value of over £3.0 million

* Changing sales mix and continued expansion into other disease areas

Chief executive Derek Hill said: "During the year, we continued to win and deliver on business providing our digital technology and services to customers in the pharmaceutical industry, both to support clinical development and to accompany market drugs in the clinic.

"The beta testing of Assessa PML, with financial support from Biogen, for use alongside their multiple sclerosis drug Tysabri demonstrates how our technology can translate from the clinical trial market into the market for companion products. Our new contracts should ensure revenue growth going forward, as these multi-year projects gather momentum."

Story provided by